Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00881413Phase 4Withdrawn

Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding

Role: collaborator

NCT00663897Phase 4Completed

Lansoprazole Versus Mosapride for Functional Dyspepsia

Role: collaborator

NCT00729339Phase 4Completed

Role of Mosapride in Patients With Gastroesophageal Reflux Disease

Role: collaborator

All 3 trials loaded